Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with ...
The New Yorker

Sam Altman May Control Our Future—Can He Be Trusted?

For weeks, they’d been having furtive discussions about whether Sam Altman, OpenAI’s C.E.O., and Greg Brockman, his second-in ...

The Media Front: Why OpenAI Bought Tech Talk Show TBPN

In this week's column, OpenAI buys TBPN, TMZ ambushes Congress, NYT cuts ties with writer, DC media scramble and a ‘60 ...